Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AQITP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RG-7636
|
|||||
| Synonyms |
DEDN-6526A; RG7636; RG 7636
Click to Show/Hide
|
|||||
| Organization |
Genentech, Inc.; Roche Holding AG
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Melanoma [ICD11:2C30]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
3-4
|
|||||
| Structure |
|
|||||
| Antibody Name |
MEDN6000A
|
Antibody Info | ||||
| Antigen Name |
Endothelin receptor type B (EDNRB)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.